Diagnostic utility of a-methylacyl COA racemase in prostate cancer of the Iranian population

• Published in: Journal of research in medical sciences Vol. 26; no. 1; p. 46
• Main Authors: Taheri, Diana, Roohani, Elham, Izadpanahi, Mohammad Hossein, Dolatkhah, Shahaboddin, Aghaaliakbari, Farshad, Daneshpajouhnejad, Parnaz, Gharaati, Mohammad Reza, Mazdak, Hamid, Fesharakizadeh, Shahriar, Beinabadi, Yasasmin, Kazemi, Reza, Rahbar, Mahtab
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer - Medknow 01.01.2021; Wolters Kluwer Medknow Publications
• Subjects: adenocarcinoma; alpha-methylacyl-coa racemase; biomarker; Original; prostate; Adenocarcinoma; prostate; alpha-methylacyl-CoA racemase; biomarker
• ISSN: 1735-1995; 1735-7136
• DOI: 10.4103/jrms.JRMS_311_19

Considering the great variations in the reported prevalence of prostate cancer across the world possibly due to different genetic and environmental backgrounds, we aimed to determine the expression pattern and the diagnostic utility of α-methylacyl coenzyme A racemase (AMACR) among Iranian patients with prostate adenocarcinoma. In this cross-sectional study, formalin-fixed paraffin-embedded tissues of 58 patients with a definitive pathologic diagnosis of prostatic adenocarcinoma were evaluated. The expression of AMACR, intensity, and extensity of its staining was determined in selected samples by immunohistochemical technique. AMACR expression was significantly higher in neoplastic compared to normal tissue ( < 0.05). The expression of AMACR was significantly associated with the age of the patients ( = 0.04). The intensity of the staining was associated with the grade of the prostate adenocarcinoma ( = 0.04). There was no significant relationship between AMACR expression and perineural invasion. The sensitivity, specificity, positive predictive value, and negative predictive value of AMACR were 90%, 96%, 96%, and 90%, respectively. Findings from our study indicate that AMACR could be used as a diagnostic tool for the diagnosis of prostate adenocarcinoma. However, due to false-positive staining in the mimicker of prostatic adenocarcinoma, it is recommended to use it in combination with basal cell markers.